Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Yarchoan Website

Robert Yarchoan, M.D.

Selected Publications

1)  Yarchoan R, eds.
Cancer in People with HIV and AIDS: Progress and Challenges.
New York: Springer Science & Business Media; 2014. [Book (Editor)]
2)  Yarchoan R, Undrick T, Polizzotto M.
Yarchoan R, eds.
HIV-Associated Cancers. In: Cancers in People with HIV and AIDS: Progress and Challenges.
New York: Springer Science & Business Media; 2014. p. 1-15 [Book Chapter]
3)  Polizzotto M, Undrick T, Yarchoan R.
Multicentric Castleman Disease. In: Cancers in People with HIV and AIDS: Progress and Challenges.
New York: Springer Science & Business Media; 2014. p. 245-260 [Book Chapter]
4)  Shahbazi S, Peer CJ, Polizzotto MN, Uldrick TS, Roth J, Wyvill KM, Aleman K, Zeldis JB, Yarchoan R, Figg WD.
A sensitive and robust HPLC assay with fluorescence detection for the quantification of pomalidomide in human plasma for pharmacokinetic analyses.
J Pharm Biomed Anal. 92: 63-8, 2014.
5)  Daniels SI, Soule EE, Davidoff KS, Bernbaum JG, Hu D, Maeda K, Stahl SJ, Naiman NE, Waheed AA, Freed EO, Wingfield P, Yarchoan R, Davis DA.
Activation of virus uptake through induction of macropinocytosis with a novel polymerizing peptide.
FASEB J. 28: 106-16, 2014.
6)  Polizzotto MN, Uldrick TS, Yarchoan R.
Case 29-2013: An HIV-positive man with dyspnea and skin lesions.
N. Engl. J. Med. 370: 87-8, 2014.
7)  Labo N, Miley W, Marshall V, Gillette W, Esposito D, Bess M, Turano A, Uldrick T, Polizzotto MN, Wyvill KM, Bagni R, Yarchoan R, Whitby D.
Heterogeneity and Breadth of Host Antibody Response to KSHV Infection Demonstrated by Systematic Analysis of the KSHV Proteome.
PLoS Pathog. 10: e1004046, 2014.
8)  Yarchoan R, Mitsuya H.
LeGrice S, Gotte M, eds.
Development of the first AIDS drugs: AZT and other dideoxynucleosides. In: Human Immunodeficiency Virus Reverse Transcriptase: A Bench-to-Bedside Success.
New York: Springer; 2013. p. 1-22 [Book Chapter]
9)  Venkataraman G, Uldrick TS, Aleman K, O'Mahony D, Karcher DS, Steinberg SM, Raffeld MA, Marshall V, Whitby D, Little RF, Yarchoan R, Pittaluga S, Maric I.
Bone Marrow Findings in HIV-Positive Patients With Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease.
Am. J. Clin. Pathol. 139: 651-61, 2013.
10)  Kainerstorfer JM, Polizzotto MN, Uldrick TS, Rahman R, Hassan M, Najafizadeh L, Ardeshirpour Y, Wyvill KM, Aleman K, Smith PD, Yarchoan R, Gandjbakhche AH.
Evaluation of non-invasive multispectral imaging as a tool for measuring the effect of systemic therapy in Kaposi sarcoma.
PLoS ONE. 8: e83887, 2013.
11)  Polizzotto MN, Uldrick TS, Wang V, Aleman K, Wyvill KM, Marshall V, Pittaluga S, O'Mahony D, Whitby D, Tosato G, Steinberg SM, Little RF, Yarchoan R.
Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease.
Blood. 122: 4189-98, 2013.
12)  O'Mahony D, Little RF, Yarchoan R.
LaFond RE, eds.
AIDS and cancer. In: Cancer - The Outlaw Cell.
New York: American Chemical Society and Oxford University Press USA; 2012. p. 165-178 [Book Chapter]
13)  Sakakibara S, Espigol-Frigole G, Gasperini P, Uldrick TS, Yarchoan R, Tosato G.
A20/TNFAIP3 inhibits NF-κB activation induced by the Kaposi's sarcoma-associated herpesvirus vFLIP oncoprotein.
Oncogene. 32: 1223-32, 2012.
14)  Davis DA, Soule EE, Davidoff KS, Daniels SI, Naiman NE, Yarchoan R.
Activity of human immunodeficiency virus type 1 protease inhibitors against the initial autocleavage in Gag-Pol polyprotein processing.
Antimicrob. Agents Chemother. 56: 3620-8, 2012.
15)  Polizzotto MN, Uldrick TS, Hu D, Yarchoan R.
Clinical Manifestations of Kaposi Sarcoma Herpesvirus Lytic Activation: Multicentric Castleman Disease (KSHV-MCD) and the KSHV Inflammatory Cytokine Syndrome.
Front Microbiol. 3: 73, 2012.
16)  Gasperini P, Espigol-Frigole G, McCormick PJ, Salvucci O, Maric D, Uldrick TS, Polizzotto MN, Yarchoan R, Tosato G.
Kaposi sarcoma herpesvirus promotes endothelial-to-mesenchymal transition through Notch-dependent signaling.
Cancer Res. 72: 1157-69, 2012.
17)  Abend JR, Ramalingam D, Kieffer-Kwon P, Uldrick TS, Yarchoan R, Ziegelbauer JM.
Kaposi"s Sarcoma-Associated Herpesvirus MicroRNAs Target IRAK1 and MYD88, Two Components of the Toll-Like Receptor/Interleukin-1R Signaling Cascade, To Reduce Inflammatory-Cytokine Expression.
J. Virol. 86: 11663-74, 2012.
18)  Veeranna RP, Haque M, Davis DA, Yang M, Yarchoan R.
Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen induction by hypoxia and hypoxia-inducible factors.
J. Virol. 86: 1097-108, 2012.
19)  Uldrick TS, Wyvill KM, Kumar P, O'Mahony D, Bernstein W, Aleman K, Polizzotto MN, Steinberg SM, Pittaluga S, Marshall V, Whitby D, Little RF, Yarchoan R.
Phase II Study of Bevacizumab in Patients With HIV-Associated Kaposi's Sarcoma Receiving Antiretroviral Therapy.
J. Clin. Oncol. 30: 1476-83, 2012.
20)  Uldrick TS, Polizzotto MN, Yarchoan R.
Recent advances in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease.
Curr Opin Oncol. 24: 495-505, 2012.
21)  Ray A, Marshall V, Uldrick T, Leighty R, Labo N, Wyvill K, Aleman K, Polizzotto MN, Little RF, Yarchoan R, Whitby D.
Sequence Analysis of Kaposi Sarcoma-Associated Herpesvirus (KSHV) MicroRNAs in Patients with Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome.
J. Infect. Dis. 205: 1665-76, 2012.
22)  Peer CJ, Sissung TM, Kim A, Jain L, Woo S, Gardner ER, Kirkland CT, Troutman SM, English BC, Richardson ED, Federspiel J, Venzon D, Dahut W, Kohn E, Kummar S, Yarchoan R, Giaccone G, Widemann B, Figg WD.
Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia.
Clin. Cancer Res. 18: 2099-107, 2012.
23)  Yarchoan R, Uldrick TS, Little RF.
DeVita Jr. VT, Lawrence TS, Rosenberg SA, eds.
AIDS-Related Malignancies. In: Principals and Practice of Oncology, 9th Edition.
Philadelphia: Lippincott, WIlliams, & WIlkins; 2011. p. 2099-2112 [Book Chapter]
24)  Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, Bhatia K, Uldrick TS, Yarchoan R, Goedert JJ, Engels EA.
Cancer Burden in the HIV-Infected Population in the United States.
J. Natl. Cancer Inst. 103: 753-62, 2011.
25)  Uldrick TS, Polizzotto MN, Aleman K, O'Mahony D, Wyvill KM, Wang V, Marshall V, Pittaluga S, Steinberg SM, Tosato G, Whitby D, Little RF, Yarchoan R.
High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy.
Blood. 117: 6977-86, 2011.
26)  Yu H, Tawab-Amiri A, Dzutsev A, Sabatino M, Aleman K, Yarchoan R, Terabe M, Sui Y, Berzofsky JA.
IL-15 ex vivo overcomes CD4+ T cell deficiency for the induction of human antigen-specific CD8+ T cell responses.
J. Leukoc. Biol. 90: 205-14, 2011.
27)  Kang JG, Majerciak V, Uldrick TS, Wang X, Kruhlak M, Yarchoan R, Zheng ZM.
Kaposi's sarcoma-associated herpesviral IL-6 and human IL-6 open reading frames contain miRNA binding sites and are subject to cellular miRNA regulation.
J. Pathol. 225: 378-89, 2011.
28)  Delviks-Frankenberry KA, Chaipan C, Bagni R, Wyvill K, Yarchoan R, Pathak VK.
Lack of Detection of Xenotropic Murine Leukemia Virus-Related Virus in HIV-1 Lymphoma Patients.
Adv Virol. 2011: 797820, 2011.
29)  Jain L, Woo S, Gardner ER, Dahut WL, Kohn EC, Kummar S, Mould DR, Giaccone G, Yarchoan R, Venitz J, Figg WD.
Population pharmacokinetic analysis of sorafenib in patients with solid tumours.
Br J Clin Pharmacol. 72: 294-305, 2011.
30)  Uldrick TS, Wang V, O'Mahony D, Aleman K, Wyvill KM, Marshall V, Steinberg SM, Pittaluga S, Maric I, Whitby D, Tosato G, Little RF, Yarchoan R.
An Interleukin-6-Related Systemic Inflammatory Syndrome in Patients Co-Infected with Kaposi Sarcoma-Associated Herpesvirus and HIV but without Multicentric Castleman Disease.
Clin. Infect. Dis. 51: 350-8, 2010.
31)  Tang S, Zhao J, Wang A, Viswanath R, Harma H, Little RF, Yarchoan R, Stramer SL, Nyambi PN, Lee S, Wood O, Wong EY, Wang X, Hewlett IK.
Characterization of Immune Responses to Capsid Protein (p24) of Human Immunodeficiency Virus Type 1: Implications for Detection.
Clin. Vaccine Immunol. 17: 1244-51, 2010.
32)  Wang V, Davis DA, Veeranna RP, Haque M, Yarchoan R.
Characterization of the activation of protein tyrosine phosphatase, receptor-type, Z polypeptide 1 (PTPRZ1) by hypoxia inducible factor-2 alpha.
PLoS ONE. 5: e9641, 2010.
33)  Mbisa GL, Miley W, Gamache CJ, Gillette WK, Esposito D, Hopkins R, Busch MP, Schreiber GB, Little RF, Yarchoan R, Ortiz-Conde BA, Labò N, Whitby D.
Detection of antibodies to Kaposi's sarcoma-associated herpesvirus: A new approach using K8.1 ELISA and a newly developed recombinant LANA ELISA.
J. Immunol. Methods. 356: 39-46, 2010.
34)  Burbelo PD, Issa AT, Ching KH, Wyvill KM, Little RF, Iadarola MJ, Kovacs JA, Yarchoan R.
Distinct profiles of antibodies to Kaposi sarcoma-associated herpesvirus antigens in patients with Kaposi sarcoma, multicentric Castleman disease, and primary effusion lymphoma.
J. Infect. Dis. 201: 1919-22, 2010.
35)  Jain L, Sissung TM, Danesi R, Kohn EC, Dahut WL, Kummar S, Venzon D, Liewehr D, English BC, Baum CE, Yarchoan R, Giaccone G, Venitz J, Price DK, Figg WD.
Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib.
J. Exp. Clin. Cancer Res. 29: 95, 2010.
36)  Valentin A, Morrow M, Poirier RH, Aleman K, Little R, Yarchoan R, Pavlakis GN.
Identification of a Potential Pharmacological Sanctuary for HIV Type 1 in a Fraction of CD4(+) Primary Cells.
AIDS Res. Hum. Retroviruses. 26: 79-88, 2010.
37)  Housri N, Yarchoan R, Kaushal A.
Radiotherapy for patients with the human immunodeficiency virus: Are special precautions necessary?.
Cancer. 116: 273-83, 2010.
38)  Daniels SI, Davis DA, Soule EE, Stahl SJ, Tebbs IR, Wingfield P, Yarchoan R.
The Initial Step in Human Immunodeficiency Virus Type 1 GagProPol Processing Can Be Regulated by Reversible Oxidation.
PLoS ONE. 5: e13595, 2010.
39)  Dunleavy K, Little RF, Pittaluga S, Grant N, Wayne AS, Carrasquillo JA, Steinberg SM, Yarchoan R, Jaffe ES, Wilson WH.
The role of tumor histogenesis, FDG-PET, and short course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma.
Blood. 115: 3017-24, 2010.
40)  Yarchoan R, Pauza CD.
Cancers and HIV Infection: An evolving story. In: From Cause to Care. Commemorating 25 Years of HIV/AIDS Research.
Washington, DC: American Association for the Advancement of Science; 2009. p. 38-40 [Book Chapter]
41)  Davis DA, Tebbs IR, Daniels SI, Stahl SJ, Kaufman JD, Wingfield P, Bowman MJ, Chmielewski J, Yarchoan R.
Analysis and characterization of dimerization inhibition of a multi-drug-resistant human immunodeficiency virus type 1 protease using a novel size-exclusion chromatographic approach.
Biochem. J. 419: 497-506, 2009.
42)  Yarchoan R, Little RF.
DeVita, Jr. VT, Lawrence TS, Rosenberg SA, eds.
AIDS-Related Malignancies. In: Cancer: Principles and Practice of Oncology, 8th Edition.
Baltimore: Lippincott, Williams, & WIlkins; 2008. p. 2401-17 [Book Chapter]
43)  Morrow M, Valentin A, Little R, Yarchoan R, Pavlakis GN.
A Splenic Marginal Zone-Like Peripheral Blood CD27(+)B220() B Cell Population Is Preferentially Depleted in HIV Type 1-Infected Individuals.
AIDS Res. Hum. Retroviruses. 24: 621-33, 2008.
44)  O'Mahony D, Gandjbakche A, Hassan M, Vogel A, Yarchoan R.
Imaging techniques for Kaposi's sarcoma.
J. HIV Ther. 13: 65-71, 2008.
45)  Little RF, Pittaluga S, Yarchoan R.
Dolin R, Masur H, Saag M, eds.
Non-Hodgkin lymphoma. In: AIDS Therapy, 3rd Edition.
Philadelphia: Chrchill Livingstone/Elsevier; 2007. p. 1031-1050. [Book Chapter]
46)  Marshall V, Parks T, Bagni R, Wang CD, Samols MA, Hu J, Wyvil KM, Aleman K, Little RF, Yarchoan R, Renne R, Whitby D.
Conservation of Virally Encoded MicroRNAs in Kaposi Sarcoma-Associated Herpesvirus in Primary Effusion Lymphoma Cell Lines and in Patients with Kaposi Sarcoma or Multicentric Castleman Disease.
J. Infect. Dis. 195: 645-59, 2007.
47)  Davis DA, Singer KE, Reynolds IP, Haque M, Yarchoan R.
Hypoxia enhances the phosphorylation and cytotoxicity of ganciclovir and zidovudine in Kaposi's sarcoma-associated herpesvirus infected cells.
Cancer Res. 67: 7003-10, 2007.
48)  Hazra R, Jankelevich S, Mackall CL, Avila NA, Wolters P, Civitello L, Christensen B, Jacobsen F, Steinberg SM, Yarchoan R.
Immunologic, virologic, and neuropsychologic responses in human immunodeficiency virus-infected children receiving their first highly active antiretroviral therapy regimen.
Viral Immunol. 20: 131-41, 2007.
49)  Tang S, Zhao J, Storhoff JJ, Norris PJ, Little RF, Yarchoan R, Stramer SL, Patno T, Domanus M, Dhar A, Mirkin CA, Hewlett IK.
Nanoparticle-Based biobarcode amplification assay (BCA) for sensitive and early detection of human immunodeficiency type 1 capsid (p24) antigen.
J. Acquir. Immune Defic. Syndr. 46: 231-7, 2007.
50)  Little RF, Aleman K, Kumar P, Wyvill KM, Pluda JM, Read-Connole E, Wang V, Pittaluga S, Catanzaro AT, Steinberg SM, Yarchoan R.
Phase 2 study of pegylated liposomal doxorubicin in combination with interleukin-12 for AIDS-related Kaposi sarcoma.
Blood. 110: 4165-71, 2007.
51)  Koh Y, Matsumi S, Das D, Amano M, Davis DA, Li J, Leschenko S, Baldridge A, Shioda T, Yarchoan R, Ghosh AK, Mitsuya H.
Potent Inhibition of HIV-1 Replication by Novel Non-peptidyl Small Molecule Inhibitors of Protease Dimerization.
J. Biol. Chem. 282: 28709-20, 2007.
52)  Yarchoan R, Pluda JM, Wyvill KM, Aleman K, Rodriguez-Chavez IR, Tosato G, Catanzaro AT, Steinberg SM, Little RF.
Treatment of AIDS-related Kaposi's sarcoma with interleukin-12: rationale and preliminary evidence of clinical activity.
Crit. Rev. Immunol. 27: 401-14, 2007.
53)  Vogel A, Chernomordik VV, Riley JD, Hassan M, Amyot F, Dasgeb B, Demos SG, Pursley R, Little RF, Yarchoan R, Tao Y, Gandjbakhche AH.
Using noninvasive multispectral imaging to quantitatively assess tissue vasculature.
J Biomed Opt. 12: 051604, 2007.
54)  Tosato G, Little RF, Yarchoan R.
Young NS, Gerson SL, High KA, eds.
Epstein-Barr virus-related and Kaposi's sarcoma associated herpesvirus-related neoplasms. In: Clinical Hematology.
Philadelphia, PA: Elsevier; 2006. p. 610-624 [Book Chapter]
55)  Hassan M, Chernomordik V, Vogel A, Hattery D, Gannot I, Yarchoan R, Gandjibakhche A.
Infrared imaging for tissue characterization and function. In: The Biomedical Engineering Handbook, Third Edition, Bronzino JD, Ed.
Boca Raton, FL: CRC Press; 2006. p. 30-1 - 30-25 [Book Chapter]
56)  Bernstein WB, Little RF, Wilson WH, Yarchoan R.
Acquired immunodeficiency syndrome-related malignancies in the era of highly active antiretroviral therapy.
Int. J. Hematol. 84: 3-11, 2006.
57)  Little RF, Pluda JM, Wyvill KM, Rodriguez-Chavez IR, Tosato G, Catanzaro AT, Steinberg SM, Yarchoan R.
Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma.
Blood. 107: 4650-7, 2006.
58)  Haque M, Wang V, Davis DA, Zheng ZM, Yarchoan R.
Genetic Organization and Hypoxic Activation of the Kaposi's Sarcoma-Associated Herpesvirus ORF34-37 Gene Cluster.
J. Virol. 80: 7037-51, 2006.
59)  Davis DA, Brown CA, Singer KE, Wang V, Kaufman J, Stahl SJ, Wingfield P, Maeda K, Harada S, Yoshimura K, Kosalaraksa P, Mitsuya H, Yarchoan R.
Inhibition of HIV-1 replication by a peptide dimerization inhibitor of HIV-1 protease.
Antiviral Res. 72: 89-99, 2006.
60)  Yarchoan R.
Key role for a viral lytic gene in Kaposi's sarcoma.
N. Engl. J. Med. 355: 1383-5, 2006.
61)  Yarchoan R, Haque M.
KSHV wages a two-front war on PECAM/CD31 [Editorial].
Blood. 108: 1790-1791, 2006.
Full Text Article. [Journal]
62)  Little RF, Yarchoan R.
Poor specific T cell responses to human herpesvirus 8: a key to unleashing kaposi sarcoma?.
J. Infect. Dis. 194: 1030-1, 2006.
63)  Okazaki T, Terabe M, Catanzaro AT, Pendleton CD, Yarchoan R, Berzofsky JA.
Possible therapeutic vaccine strategy against human immunodeficiency virus escape from reverse transcriptase inhibitors studied in HLA-A2 transgenic mice.
J. Virol. 80: 10645-51, 2006.
64)  Semenova EA, Johnson AA, Marchand C, Davis DA, Yarchoan R, Pommier Y.
Preferential Inhibition of the Magnesium-Dependent Strand Transfer Reaction of HIV-1 Integrase by {alpha}-Hydroxytropolones.
Mol Pharmacol. 69: 1454-60, 2006.
65)  Vogel A, Dasgeb B, Hassan M, Amyot F, Chernomordik V, Tao Y, Demos SG, Wyvill K, Aleman K, Little R, Yarchoan R, Gandjbakhche AH.
Using Quantitative Imaging Techniques to Assess Vascularity in AIDS-Related Kaposi's Sarcoma.
Conf Proc IEEE Eng Med Biol Soc. 1: 232-5, 2006.
66)  Yarchoan R, Little RF.
DeVita Jr VT, Hellman S, Rosenberg SA, eds.
AIDS-related malignancies. In: Cancer: Principles and Practice of Oncology, 7th Edition.
Philadelphia: Lippincott Williams and Wilkins; 2005. p. 2247-2262 [Book Chapter]
67)  Wang V, Davis DA, Haque M, Huang LE, Yarchoan R.
Differential gene up-regulation by hypoxia-inducible factor-1alpha and hypoxia-inducible factor-2alpha in HEK293T cells.
Cancer Res. 65: 3299-306, 2005.
68)  Davis DA, Singer KE, De La Luz Sierra M, Narazaki M, Yang F, Fales HM, Yarchoan R, Tosato G.
Identification of carboxypeptidase N as an enzyme responsible for C-terminal cleavage of stromal cell-derived factor-1alpha in the circulation.
Blood. 105: 4561-8, 2005.
69)  Gandjbakhche A, Vogel A, Amyot F, Chernomordik V, Hassan M, Demos S, Aleman K, Little R, Yarchoan R.
Noninvasive Multimodality Imaging Techniques to Assess Kaposi's Sarcoma.
Conf Proc IEEE Eng Med Biol Soc. 1: 694-6, 2005.
70)  Yarchoan R, Tosato G, Little RF.
Therapy Insight: AIDS-related malignancies: the influence of antiviral therapy on pathogenesis and management.
Nat Clin Pract Oncol. 2: 406-15, 2005.
Click Here to View Collapsed Bibliography.

This page was last updated on 7/28/2014.